Volume surge masks the margin squeeze

Cosmo First's quarter sits at an awkward fulcrum. On the headline, ₹1,166 crore in revenue represents a stunning 46% YoY jump—driven cleanly by 9% volume growth and a 37% price realization from raw material pass-through following the West Asia conflict. The company achieved a strategic watershed: all B2B businesses (films, Specialty Chemicals, Plastech, and consumer arms Zigly and Cosmo Consumer) are now EBITDA positive. The ₹1,200 crore capex cycle is largely complete, pivoting the company from build to leverage mode. Yet that same result shows EBITDA margins compressed 190 basis points to 12.6%, and net profit grew only 25%—a lag that signals the margin story is real, not optical.

On a per-kilogram basis, Cosmo's story improves: EBITDA per kg rose 15% despite only 9% volume growth, showing underlying operational health. But the 190 basis point margin compression in percentage terms reflects the economics of a pass-through business—raw material prices inflate, companies pass the delta to customers, but the margin % shrinks even as absolute contribution improves. Management's detail here was credible: they showed per-kg contribution up across all product categories, and the EBITDA/kg math validates their claim that the real operating story sits in per-unit economics, not margin %.

The PAT lag, however, is structural and near-term concerning. Revenue +46%, EBITDA +26%, PAT +25% shows weak operating leverage. The culprit: new capex is now hitting depreciation and interest headwinds. The company invested ₹1,200 crore over three years; that capital is depreciating and its debt servicing costs are eating into profits faster than EBITDA is compounding. This is temporary—leverage improves as EBITDA grows into the installed base—but it explains why management reaffirmed a 20% FY27 topline guidance rather than raising it. The quarter was good, but not a signal that the full year will repeat 46%.

The stock closed at ₹916 on August 13—4.08% below its all-time high and comfortably above its 20-, 50-, and 200-day simple moving averages (SMA20 ₹888, SMA50 ₹828, SMA200 ₹733). The technical setup is solid: up 63% off its 52-week low and trending higher. Post-result price action was positive but not euphoric. The day-1 pop of +1.77% expanded to +6.08% by day 3, then settled to +4.45% by day 5—the pop held, suggesting the market took the result constructively but without conviction of a step-change. RSI stands at 59.8 (neutral, not overbought), leaving room to run if fundamentals hold.

Institutional flows are cautiously supportive. FII holdings inched up 0.28 percentage points to 2.41% (from 2.13% in Q4), while DII added 0.36 percentage points to 1.49% (from 1.13%). Promoter holdings remain steady at 41.24%. The incremental buying is deliberate, not aggressive—institutions are slowly building but not rushing. Volume is increasing, suggesting retail participation is broadening. This matches our read: the quarter merits a constructive but not bullish stance. Near-term margin headwinds and execution risk (ROCE, Zigly breakeven, BOPET recovery) keep conviction tempered.

The honest read: Cosmo delivered on strategic milestones (all B2B profitable, capex done, new businesses scaling) but at a cost: margins compressed, profit growth lagged, and near-term headwinds (BOPET, export logistics, consumer burn, raw material volatility) dominate. The medium-term bull case (capex leverage, specialty mix, ROCE improvement) is credible but depends on flawless execution and a stable macro environment. At ₹916, near its all-time high, the stock has priced in much of the optimism. Hold is warranted; a new entry on a 10–12% pullback would be more prudent.